This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2023)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2023)	Global Fund ERP recommended	GDF Catalog	Status Yes No Removed Ineligible for inclusion N/A
Amoxicillin/clavulanate 500mg/125mg tablet												
Amoxicillin/clavulanic acid 250mg/62.5mg/5mL oral suspension												
Bedaquiline 20mg tablet												
Bedaquiline 100mg tablet												
Clofazimine 50mg tablet/capsule												
Cycloserine 125mg capsule												
Delamanid 25mg dispersible tablet												_


DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.



DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Pregualification of Medicines Programme

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2023)	WHO PQ E01 (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2023)	Global Fund ERP recommended	GDF Catalog	Status Yes No Removed Ineligible for inclusion N/A
Isoniazid 100mg dispersible tablet												
Isoniazid 100mg tablet												
Isoniazid 300mg tablet/capsule												
Levofloxacin 100mg dispersible tablet												
Linezolid 20mg/mL oral suspension												_
Linezolid 150mg dispersible tablet												
Linezolid 600mg tablet												_


DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.



DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest
ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Pregualification of Medicines Programme

This Dashboard has been developed by Stop TB Partnership/Global Drug Facility in collaboration with USAID, the World Health Organization and The Global Fund to fight AIDS, TB & Malaria.

Stop TB Partnership/Global Drug Facility licensed the TB Medicines Dashboard under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Medicines	WHO Guidelines (DR-TB '20)	WHO Guidelines (Children & Adolescent '22)	EMLc submitted	EMLc (2023)	WHO PQ EOI (2021)	WHO PQ Dossier Under Review	WHO PQ listed	Global Fund List of Pharmaceutical Products	Global Fund ERP EOI (July 2023)	Global Fund ERP recommended	GDF Catalog	Status Yes No Removed Ineligible for inclusion N/A
Pyrazinamide 150mg dispersible tablet												

DR-TB: Drug-Resistant TB
EML: Essential Medicines List
EOI: Expression of Interest

ERP: Expert Review Panel

SRA: Stringent Regulatory Authority

WHO PQ: World Health Organization Prequalification of Medicines Programme